High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Lung Cancer

Volumn 98, Issue , 2016, Pages 59-61

  Ou, Sai Hong Ignatius ^a   Agarwal, Nikita ^b   Ali, Siraj M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

Acquired resistance; METamplification; Non small cell lung cancer; Osimertinib; Third generation EGFR TKI

Indexed keywords

AFATINIB; CARBOPLATIN; CRIZOTINIB; ERLOTINIB; GEMCITABINE; OSIMERTINIB; PEMETREXED; SCATTER FACTOR RECEPTOR; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESISTANCE; DRUG WITHDRAWAL; DYSPNEA; EXON; FATIGUE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; LEG EDEMA; LIQUEFACTION; LUNG ADENOCARCINOMA; LUNG BIOPSY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; DISEASE EXACERBATION; DRUG SUBSTITUTION; FATALITY; GENETICS; LUNG TUMOR; RETREATMENT; X-RAY COMPUTED TOMOGRAPHY;

ACRYLAMIDES; AGED; ANILINE COMPOUNDS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; FATAL OUTCOME; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RETREATMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84973438966     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.05.015     Document Type: Article

References (14)

1. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3(March (75)). 75ra26.
2. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
3. Jänne P.A., Yang J.C., Kim D.W., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:1689-1699.
4. Frampton G.M., Fichtenholtz A., Otto G.A., et al. Development and validation of a linical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 3:1023-1031.
5. Cross D.A., Ashton S.E., Ghiorghiu S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014, 4:1046-1061.
6. Yu H.A., Tian S.K., Drilon A.E., et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 2015, 1:982-984.
7. Thress K.S., Paweletz C.P., Felip E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015, 21:560-562.
8. Niederst M.J., Hu H., Mulvey H.E., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 2015, 21:3924-3933.
9. Song H.N., Jung K.S., Yoo K.H., et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J. Thorac. Oncol. 2015, (December). pii: S1556-0864(15)00209-9 (epub ahead of print). 10.1016/j.jtho.2015.12.093.
10. Planchard D., Loriot Y., André F., et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 2015, 26:2073-2078.
11. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19(9):2240-2247.
12. Ou S.H., Kwak E.L., Siwak-Tapp C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 2011, 6:942-946.
13. Kim T.M., Song A., Kim D.W., et al. Mechanisms of acquired resistance to AZD9291, a mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 2015, 10:1736-1744.
14. Amato K.R., Wang S., Tan L., et al. EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer. Cancer Res. 2016, 76:305-318.